Johnson & Johnson’s single-dose vaccine protects against COVID-19, according to an analysis by U.S. regulators Wednesday that sets the stage for a final decision on a new and easier-to-use shot to help tame the pandemic.

The Food and Drug Administration’s scientists confirmed that overall the vaccine is about 66% effective at preventing moderate to severe COVID-19. The agency also said J&J’s shot — one that could help speed vaccinations by requiring just one dose instead of two — is safe to use.

That’s just one step in the FDA’s evaluation of a third vaccine option for the U.S. On Friday, the agency’s independent advisers will debate if the evidence is strong enough to recommend the long-anticipated shot. Armed with that advice, FDA is expected to make a final decision within days.

The vaccination drive has been slower than hoped, hampered by logistical issues and weather delays even as the country mourns more than 500,000 virus-related deaths. So far, about 44.5 million Americans have received at least one dose of vaccine made by Pfizer or Moderna, and nearly 20 million have received the second dose required for full protection.

J&J tested its single-dose option in 44,000 people in the U.S., Latin America and South Africa. Different mutated versions of the virus are circulating in different countries, and the FDA analysis cautioned that it’s not clear how well the vaccine works against each variant. But J&J previously announced the vaccine worked better in the U.S. — 72% effective against moderate to severe COVID-19, compared with 66% in Latin America and 57% in South Africa.

Still, in every country it was highly effective against the most serious symptoms, and early study results showed no hospitalizations or deaths starting 28 days after vaccination.

While the overall effectiveness numbers may suggest the J&J candidate isn’t quite as strong as two-dose competitors, all of the world’s COVID-19 vaccines have been tested differently, making comparisons nearly impossible. While it wouldn’t be surprising if one dose turns out to be a little weaker than two doses, policymakers will decide if that’s an acceptable trade-off to get more people vaccinated faster.

J&J was on track to become the world’s first one-dose option until earlier this month, Mexico announced it would use a one-dose version from China’s CanSino. That vaccine is made with similar technology as J&J’s but initially was developed as a two-dose option until beginning a one-dose test in the fall.

The rival Pfizer and Moderna vaccines being used in the U.S. and numerous other countries must be kept frozen, while the J&J shot can last three months in the refrigerator, making it easier to handle. AstraZeneca’s vaccine, widely used in Europe, Britain and Israel, is made similarly and also requires refrigeration but takes two doses.

If the FDA clears the J&J shot for U.S. use, it won’t boost vaccine supplies significantly right away. Only a few million doses are expected to be ready for shipping in the first week. But J&J told Congress this week that it expected to provide 20 million doses by the end of March and 100 million by summer.

European regulators and the World Health Organization also are considering J&J’s vaccine. Worldwide, the company aims to be producing around a billion doses by the end of the year.

 

Photo via Johnson & Johnson.

 

Related Stories
‹
Gov. Cooper: Remaining Essential Workers in Group 3 to Become Vaccine-Eligible on Wednesday
North Carolina Governor Roy Cooper shared updates to the state’s coronavirus vaccination efforts Tuesday, saying essential workers in Group 3 will become eligible to make appointments beginning on Wednesday. The announcement comes nearly one week after prioritized education personnel in Group 3 became eligible to make appointments for vaccination across North Carolina. Around 240,000 people, […]
Winter Weather Slows COVID-19 Vaccine Shipments to NC, Orange County
North Carolina state leaders said Thursday the winter weather experienced in many parts of the country have caused shipping delays to doses of the COVID-19 vaccine.
J&J 1-Dose Shot Prevents COVID-19, but Less Than Some Others
Johnson & Johnson’s long-awaited vaccine appears to protect against COVID-19 with just one shot – not as strong as some two-shot rivals but still potentially helpful for a world in dire need of more doses. J&J said Friday that in the U.S. and seven other countries, the single-shot vaccine was 66% effective overall at preventing moderate […]
India Starts Booster Shots for Vulnerable Amid Omicron Surge
Written by ANIRUDDHA GHOSAL Healthcare and front-line workers along with people above age 60 with health problems lined up Monday at vaccination centers across India to receive a third dose as infections linked to the omicron variant surge. The doses, which India is calling a “precautionary” shot instead of a booster, were given as new […]
Pfizer Says COVID Booster Offers Protection Against Omicron
Written by LAURAN NEERGAARD Pfizer said Wednesday that a booster dose of its COVID-19 vaccine may offer important protection against the new omicron variant even though the initial two doses appear significantly less effective. Pfizer and its partner BioNTech said that while two doses may not be protective enough to prevent infection, lab tests showed a booster […]
US Gives Final Clearance to COVID-19 Shots for Kids 5 to 11
U.S. health officials on Tuesday gave the final signoff to Pfizer’s kid-size COVID-19 shot, a milestone that opens a major expansion of the nation’s vaccination campaign to children as young as 5. The Food and Drug Administration already authorized the shots for children ages 5 to 11 — doses just a third of the amount […]
Moderna Says Its COVID-19 Shot Works in Kids as Young as 12
Written by LAURAN NEERGAARD Moderna said Tuesday its COVID-19 vaccine strongly protects kids as young as 12, a step that could put the shot on track to become the second option for that age group in the U.S. With global vaccine supplies still tight, much of the world is struggling to vaccinate adults in the quest […]
UNC Health to Resume Johnson & Johnson COVID-19 Vaccinations
Beginning Wednesday, May 5, UNC Health will resume offering the Johnson & Johnson COVID-19 vaccine after a three-week pause. According to a release from the healthcare system, “Our experts have reviewed the data and CDC recommendations to resume Johnson and Johnson COVID-19 vaccines, and continue to strongly recommend patients receive any one of the COVID-19 […]
U.S. Drop In Vaccine Demand Has Some Places Turning Down Doses
Written by LEAH WILLINGHAM, HEATHER HOLLINGSWORTH and MICHELLE R. SMITH Louisiana has stopped asking the federal government for its full allotment of COVID-19 vaccine. About three-quarters of Kansas counties have turned down new shipments of the vaccine at least once over the past month. And in Mississippi, officials asked the federal government to ship vials in […]
Homeless Americans Finally Getting a Chance at COVID-19 Shot
Written by CARLA K. JOHNSON Homeless Americans who have been left off priority lists for coronavirus vaccinations — or even bumped aside as states shifted eligibility to older age groups — are finally getting their shots as vaccine supplies increase. While the U.S. government has only incomplete data on infections among homeless people, it’s clear that crowded, unsanitary […]
›